Laboratory confirmed COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Group A.: The standard drug treatment is based on the treatment protocols of the National Committee of COVID-19 and erythropoietin recombinant (EPREX Manufactured b
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 65 Years
Inclusion criteria
Inclusion criteria: All definitively positive COVID-19 patients with Hb=9. Having at least one of the severe symptoms of COVID-19, including tachypnea (breathing rate> 30 beats per minute), hypoxemia (O2 =93 saturation, the partial pressure ratio of arterial oxygen 50% of lung field within 24 to 48 hours), progressive lymphopenia, LDH>245 U/I, CRP>100
Exclusion criteria
Exclusion criteria: Patients with a history of coagulopathy Patients with a history of thrombosis Patients with a history of deep vein thrombosis Patients with a history of chronic lung disease Patients with a history of diabetes mellitus Patients with weakened immune systems Patients with a history of end stage renal disease Patients with liver disease Patients with a history of taking oral contraceptive pills (OCPs) Patients with systolic blood pressure greater than 160 mmHg Patients with diastolic blood pressure greater than 90 mmHg Patients over 65 years of age Patients with erythropoietin above 500 Patients with a history of myocardial infarction or unstable angina Patients with a history of malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory rate. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Pulse oximeter.;Oxygen saturation state and arterial oxygen partial pressure ratio. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: Pulse oximeter.;Lung infiltration status. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: chest x-ray.;LDH level's. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: pathobiology laboratory.;CRP level's. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: pathobiology laboratory.;Lymphocyte count. Timepoint: At the beginning of the study (before the intervention) and day 5 after the intervention. Method of measurement: pathobiology laboratory.;Endogenous erythropoietin level's. Timepoint: Beginning of study (before intervention). Method of measurement: Pathobiology laboratory.;Patients' blood pressure. Timepoint: At the beginning of the study (before the intervention), during the intervention (5-day erythropoietin administration). Method of measurement: Sphygmomanometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients' blood hemoglobin levels. Timepoint: Start of study (before the intervention), day 5 after the intervention and 2 to 4 weeks after the intervention. Method of measurement: Pathobiology laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDariush Hooshyar
Bandare-abbas University of Medical Sciences
Outcome results
None listed